2. Search Result
Search Result
Results for "

IBD

" in MedChemExpress (MCE) Product Catalog:

120

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

12

Peptides

5

Inhibitory Antibodies

8

Natural
Products

7

Recombinant Proteins

7

Isotope-Labeled Compounds

3

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W028393
    Indole-3-pyruvic acid
    1 Publications Verification

    		 Endogenous Metabolite Aryl Hydrocarbon Receptor Neurological Disease Inflammation/Immunology
    Indole-3-pyruvic acid, a keto analogue of tryptophan, is an orally active AHR agonist. Indole-3-pyruvic acid has antioxidant properties, and can be used in the research of inflammation, anxiety .
    Indole-3-pyruvic acid
  • HY-151435
    CCR6 antagonist 1
    4 Publications Verification

    		 CCR Inflammation/Immunology
    CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs) .
    CCR6 antagonist 1
  • HY-I0447
    4-Aminosalicylic acid
    1 Publications Verification

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    4-Aminosalicylic acid is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. 4-Aminosalicylic acid exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). 4-Aminosalicylic acid is orally active .
    4-Aminosalicylic acid
  • HY-174990
    HW201877

    		15-PGDH Metabolic Disease Inflammation/Immunology
    HW201877 is a potent and orally active 15-prostaglandin dehydrogenase (15-PGDH) inhibitor with an IC50 of 3.6 nM. HW201877 demonstrates robust cellular efficacy in elevating PGE2 levels in A549 cells and exhibits remarkable efficacy in animal models of tissue injury and fibrosis. HW201877 can be used for the study of inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and Crohn’s disease (CD) .
    HW201877
  • HY-P9984
    Etrolizumab
    2 Publications Verification

    rhuMAb Beta7; RG7413; PRO145223

    		 Integrin Cancer
    Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
    Etrolizumab
  • HY-123630
    Allura Red AC

    FD&C RED NO. 40; CI 16035

    		 Environmental Pollutants Fluorescent Dye 5-HT Receptor Interleukin Related Reactive Oxygen Species (ROS) IFNAR Inflammation/Immunology
    Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .
    Allura Red AC
  • HY-14908
    Vidofludimus
    4 Publications Verification

    4sc-101; SC12267

    		 Dihydroorotate Dehydrogenase Interleukin Related FXR Infection Inflammation/Immunology
    Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .
    Vidofludimus
  • HY-115497
    BRD5529
    4 Publications Verification

    		 E1/E2/E3 Enzyme Infection Inflammation/Immunology
    BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC) .
    BRD5529
  • HY-12820
    Sibofimloc
    4 Publications Verification

    Antibiotic-202

    		 Bacterial Antibiotic Infection
    Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD) .
    Sibofimloc
  • HY-B0174
    Olsalazine Disodium
    2 Publications Verification

    		 Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine Disodium is an orally active prodrug of 5-ASA (HY-15027). Olsalazine Disodium can inhibit cells proliferation and induce apoptosis. Olsalazine Disodium can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine Disodium can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine Disodium
  • HY-108017
    Ferric maltol

    		Biochemical Assay Reagents Metabolic Disease Cancer
    Ferric maltol is an orally active monovalent iron (Fe 3+) complex. Ferric maltol is used in the study of iron deficiency anemia in inflammatory bowel disease .
    Ferric maltol
  • HY-163102
    IA-14069

    		TNF Receptor NF-κB Inflammation/Immunology
    IA-14069 is an orally active tumor necrosis factor-α (TNF-α) inhibitor. IA-14069 binds directly to TNF-α and TNF-α-triggered signaling (p-IκBα and NF-κB p65) activities. Additionally, IA-14069 exerts a suppressive effect on Dextran sodium sulfate (HY-116282C) (DSS)-induced colitis. IA-14069 can be used for the research of Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) .
    IA-14069
  • HY-16640
    TCJL37

    		JAK Inflammation/Immunology
    TCJL37 is a potent, selective, and orally bioavailable TYK2 inhibitor with a Ki of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD) .
    TCJL37
  • HY-P2221
    Glepaglutide
    1 Publications Verification

    ZP1848

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide
  • HY-B0174A
    Olsalazine
    2 Publications Verification

    		 Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Olsalazine is an orally active prodrug of 5-ASA (HY-15027). Olsalazine can inhibit cells proliferation and induce apoptosis. Olsalazine can reduce DAI and MPO activity and inhibit inflammatory cytokines levels. Olsalazine can be used for the researches of cancer, inflammation and metabolic disease, such as colorectal cancer, inflammatory bowel disease (IBD) and hyperuricemic .
    Olsalazine
  • HY-150608
    PROTAC STING Degrader-1
    1 Publications Verification

    		 PROTACs STING Inflammation/Immunology Cancer
    PROTAC STING Degrader-1 is a PROTAC degrader targeting the STING pathway with a DC50 of 3.2 μM. PROTAC STING Degrader-1 exerts high anti-inflammatory efficacy. PROTAC STING Degrader-1 can be used to study diseases such as acute kidney injury and inflammatory bowel diseases (IBDs). (Pink: STING ligand (HY-138682); Blue: CRBN ligand (HY-10984); Black: linker (HY-W015883)) .
    PROTAC STING Degrader-1
  • HY-P990297
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5)
    1 Publications Verification

    		 CCR HIV Infection Inflammation/Immunology Cancer
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV .
    Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5)
  • HY-102013
    Omilancor

    BT-11

    		 ABA Receptor Neurological Disease Inflammation/Immunology
    Omilancor (BT-11) is an orally active lanthionine synthetase cyclase-like receptor 2 (LANCL2) activator. Omilancor can be used for the study of psoriasis, inflammatory bowel disease (IBD), and Crohn's disease (CD) .
    Omilancor
  • HY-I0447A
    Sodium 4-aminosalicylate dihydrate
    1 Publications Verification

    4-Aminosalicylic acid sodium salt dihydrate

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Sodium 4-aminosalicylate dihydrate (4-Aminosalicylic acid sodium salt dihydrate) is an inhibitor for dihydrofolate reductase (DHFR) and an antituberculous agent. Sodium 4-aminosalicylate dihydrate exhibits anti-inflammatory activity and can be used in research of inflammatory bowel disease (IBD). Sodium 4-aminosalicylate dihydrate is orally active .
    Sodium 4-aminosalicylate dihydrate
  • HY-131064
    RIPK3-IN-1
    1 Publications Verification

    		 RIP kinase Inflammation/Immunology
    RIPK3-IN-1 is a RIPK3 type II DFG-out inhibitor with an IC50 of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC50s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC50 of 1.1 μM .
    RIPK3-IN-1
  • HY-120469
    2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide

    		JAK Inflammation/Immunology
    GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with Kis of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively .
    2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
  • HY-P2221B
    Glepaglutide acetate
    1 Publications Verification

    ZP1848 acetate

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide acetate
  • HY-13545
    ABT-510
    1 Publications Verification

    		 Apoptosis Inflammation/Immunology Cancer
    ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .
    ABT-510
  • HY-105092
    Tetomilast

    OPC-6535

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Tetomilast (OPC-6535) is a PDE4 inhibitor with potential for the research of inflammatory bowel disease (IBD) and chronic obstructive pulmonary disease (COPD).
    Tetomilast
  • HY-W028393R
    Indole-3-pyruvic acid (Standard)

    		Reference Standards Endogenous Metabolite Aryl Hydrocarbon Receptor Neurological Disease Inflammation/Immunology
    Indole-3-pyruvic acid (Standard) is the analytical standard of Indole-3-pyruvic acid. This product is intended for research and analytical applications. Indole-3-pyruvic acid, a keto analogue of tryptophan, is an orally active AHR agonist. Indole-3-pyruvic acid has antioxidant properties, and can be used in the research of inflammation, anxiety[1][2][3].
    Indole-3-pyruvic acid (Standard)
  • HY-109148
    Izencitinib

    TD-1473; JNJ-8398

    		 JAK Inflammation/Immunology
    Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis .
    Izencitinib
  • HY-155782
    Zharp2-1

    		RIP kinase Inflammation/Immunology
    Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). Zharp2-1 blocker muramyl dipeptide (MDP) induces growth of mononuclear cells and induces inflammatory cell factor infection. Zharp2-1 attenuates MDP-induced small inguinal peritonitis, or ameliorates by DNBS-induced large inguinal conjunctivitis .
    Zharp2-1
  • HY-13545B
    ABT-510 acetate
    1 Publications Verification

    		 Apoptosis Inflammation/Immunology Cancer
    ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .
    ABT-510 acetate
  • HY-178761
    PGK1-IN-1

    		Phosphoglycerate Kinase (PGK) Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related Inflammation/Immunology
    PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor (IC50: 33 nM). PGK1-IN-1 inhibits PGK1-mediated glycolytic metabolism and reduces glucose consumption/lactate production. PGK1-IN-1 enhances Nrf2 accumulation and HO-1 expression, and suppresses the transcription and protein levels of the inflammatory cytokines IL-1β and IL-6. PGK1-IN-1 ameliorates Dextran sulfate sodium (DSS) (HY-116282C)-induced experimental colitis in mice. PGK1-IN-1 can be used for research of inflammatory bowel disease (IBD) .
    PGK1-IN-1
  • HY-160477
    DC-SX029

    		PIKfyve NF-κB IKK Inflammation/Immunology
    DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .
    DC-SX029
  • HY-123763
    MLN3126

    		CCR Inflammation/Immunology
    MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx .
    MLN3126
  • HY-107831
    5-Acetylsalicylic acid
    1 Publications Verification

    		 Drug Derivative Inflammation/Immunology Cancer
    5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) .
    5-Acetylsalicylic acid
  • HY-151262
    JAK-IN-23
    1 Publications Verification

    		 JAK STING NF-κB STAT Inflammation/Immunology
    JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .
    JAK-IN-23
  • HY-158404
    METTL3-IN-8

    		METTL3 Inflammation/Immunology
    METTL3-IN-8 (F039-0002) is a potent METTL3 inhibitor. METTL3-IN-8 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-8
  • HY-P99184
    Abrilumab

    		Integrin Infection Inflammation/Immunology Cancer
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
    Abrilumab
  • HY-W718300
    Indole-3-pyruvic acid-d5

    		Isotope-Labeled Compounds Neurological Disease Inflammation/Immunology
    Indole-3-pyruvic acid-d5 is deuterated labeled Indole-3-pyruvic acid. Indole-3-pyruvic acid, a keto analogue of tryptophan, is an orally active AHR agonist. Indole-3-pyruvic acid has antioxidant properties, and can be used in the research of inflammation, anxiety .
    Indole-3-pyruvic acid-d5
  • HY-161735
    CXCR4-IN-3

    		CXCR Inflammation/Immunology
    CXCR4-IN-3 (compound XVI) is an orally active and potent inhibitor targeting the inflammation-related receptor CXCR4, with an IC50 of 3.2 nM. CXCR4-IN-3 exhibits potent antichemotactic activity, at 79.19±2.33% inhibition. CXCR4-IN-3 shows anti-inflammatory activity. CXCR4-IN-3 can be used for IBD (inflammatory bowel disease) research .
    CXCR4-IN-3
  • HY-149642
    hDHODH-IN-13

    		Dihydroorotate Dehydrogenase Others
    hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD .
    hDHODH-IN-13
  • HY-142834
    RORγt/DHODH-IN-2

    		ROR Dihydroorotate Dehydrogenase Inflammation/Immunology
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .
    RORγt/DHODH-IN-2
  • HY-P10839
    NBD peptide

    		NF-κB Inflammation/Immunology
    NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT .
    NBD peptide
  • HY-169402A
    PDE1-IN-9 hydrochloride

    		Phosphodiesterase (PDE) NO Synthase Reactive Oxygen Species (ROS) Interleukin Related Inflammation/Immunology
    PDE1-IN-9 (Compound 7a) hydrochloride is a selective inhibitor for phosphodiesterase 1 (PDE1), that inhibits PDE1C with an IC50 of 11 nM. PDE1-IN-9 hydrochloride reduces mRNA expression of IL-1β, IL-6, TNF-α and iNOS, inhibits the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 hydrochloride exhibits good metabolic stability in rat liver microsomes .
    PDE1-IN-9 hydrochloride
  • HY-173450
    ZL0516

    		Epigenetic Reader Domain Inflammation/Immunology
    ZL0516 is a potent, selective, and orally active BRD4 BD1 inhibitor. ZL0516 suppresses inflammatory bowel disease (IBD) by inhibiting BRD4/NF-κB signaling .
    ZL0516
  • HY-175310S
    Voderdeucitinib

    		JAK Inflammation/Immunology
    Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .
    Voderdeucitinib
  • HY-151174
    PDE4-IN-12

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PDE4-IN-12 is a potent pan-PDE4 inhibitor, with IC50s of 3.5 and 15 nM for PDE4 and PDE7, respectively (SI=2.71 and 4.27, respectively). PDE4-IN-12 shows well tolerated, can be used in study of inflammatory bowel diseases (IBDs) .
    PDE4-IN-12
  • HY-P10966A
    Tat-IKIP (46-60) TFA

    		IKK NF-κB Inflammation/Immunology
    Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60) (HY-P10966). Tat-IKIP (46-60) is a IκB kinase (IKK)-targeting membrane-penetrating peptide. Tat-IKIP (46-60) inhibits IKK activation and NF-κB targeted gene expression by disrupting the IKKβ/NEMO complex. Tat-IKIP (46-60) significantly reduces DSS (HY-116282)-induced acute inflammation in inflammatory bowel disease (IBD) mice model and attenuates Zymosan-induced acute arthritis in acute arthritis model (AAM). Tat-IKIP (46-60) can be used for inflammatory diseases research, such as IBD, pancreatitis and rheumatoid arthritis .
    Tat-IKIP (46-60) TFA
  • HY-171804
    Linvemastat

    FP-020

    		 MMP Inflammation/Immunology
    Linvemastat (Compound FC-4) is an orally active MMP-12 inhibitor (IC50: < 10  nM) with high selectivity of MMP-1, -2, -3, -7, -9, -10 and -14. Linvemastat significantly attenuates lung fibrosis in Bleomycin (HY-108345) induced unilateral lung fibrosis mice model and potently reduces kidney damage, interstitial inflammation or fibrosis in kidney fibrosis model of unilateral ureteral occlusion. Linvemastat can be used for inflammatory diseases research, such as idiopathie pulmonary fibrosis (IPF), inflammatory bowel disease (IBD) and asthma .
    Linvemastat
  • HY-15707
    NS6180
    1 Publications Verification

    		 Potassium Channel Inflammation/Immunology
    NS6180 is a new orally active KCa3.1 channel inhibitor. NS6180 inhibits cloned human KCa3.1 channels with an IC50value of 9 nM. NS6180 can be used for the research of inflammatory bowel disease (IBD) .
    NS6180
  • HY-153094
    BDM-2

    		HIV HIV Integrase Infection
    BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity .
    BDM-2
  • HY-164670
    D228

    		p38 MAPK MyD88 Inflammation/Immunology
    D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS (HY-116282C)-induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling .
    D228
  • HY-158403
    METTL3-IN-7

    		METTL3 Inflammation/Immunology
    METTL3-IN-7 (7460-0250) is a potent METTL3 inhibitor. METTL3-IN-7 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .
    METTL3-IN-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: